NCT00233597已完成3 期
A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 230
- 试验地点
- 50
- 主要终点
- The mean change in hemoglobin from baseline.
研究概览
简要总结
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients on hemodialysis.
详细描述
This study will evaluate the efficacy and safety of intravenous (IV) iron (ferumoxytol) as compared to oral iron in the treatment of anemia in hemodialysis patients receiving erythropoietin. Patients are randomized to receive either two doses of 510 mg of intravenous ferumoxytol in sequential dialysis sessions or 200 mg oral elemental iron daily for three weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients ≥18 years.
- •Chronic hemodialysis.
- •Stable supplemental EPO therapy.
- •Baseline hemoglobin of ≤ 11.5 g/dl.
排除标准
- •Women who are pregnant or who are breast feeding.
- •Received another investigational drug or device within 30 days.
- •Recent parenteral or oral iron therapy.
- •Patients with active GI bleeding or acute bleeding within 4 weeks. Patients that have other causes of anemia.
- •Major surgery within 30 days or anticipated or planned surgery during the study.
- •Patients with active infections.
- •Recent blood transfusions.
- •Patients with known allergies to iron products.
结局指标
主要结局
The mean change in hemoglobin from baseline.
次要结局
- Change in iron indices.
研究者
研究点 (50)
Loading locations...
相似试验
已完成
3 期
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsAnemiaNCT00255437AMAG Pharmaceuticals, Inc.304
已完成
3 期
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsAnemiaNCT00255424AMAG Pharmaceuticals, Inc.304
已完成
3 期
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)Non-myeloid MalignanciesChemotherapy Induced AnaemiaNCT01145638Pharmacosmos A/S350
尚未招募
不适用
Intravenous single dose iron infusioCTRI/2021/05/033579DST Chandigarh
Unknown
4 期
Intravenous Iron in Patients With Anemia of Chronic Kidney DiseaseKidney Failure, ChronicNCT00204256University Hospital Muenster50